A Phase 2 interventional study of ZW25 (Zanidatamab) in HER2-amplified Biliary Tract Cancers, sponsored by Jazz Pharmaceuticals. Completed at 67 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Biliary Tract Neoplasms with a site in China — 93 open to participants now, 111 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.
Among the 176 studies in Biliary Tract Neoplasms with a site in China, this one is the 61st largest by enrollment of the 157 interventional ones that give a count, is one of 15 that started in 2020, is one of 94 in phase 2, and was the 40th registered.
521 studies on the registry are indexed under Biliary Tract Neoplasms; 199 are open to participants now.
Browse Biliary Tract Neoplasms studies →93 of the 176 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Haitao Zhao, MD · Sites in China
Ages 18–75
Haitao Zhao, MD · Sites in China
Ages 18–80
Haitao Zhao, MD · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 123 · Phase 3 18 · Phase 4 2
First in 1997; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 58 across 427 interventional studies indexed under Biliary Tract Neoplasms.
Median enrollment 62 across the 157 interventional studies, 200 across the 19 observational. Of the 32 that completed or were terminated, 5 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 176 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 4 studies filed under Biliary Tract Neoplasms — fewer than ten, so there is no comparison to draw.
39 of the studies in Biliary Tract Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06219941AstraZenecaAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | 2026-11-17 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT07911397Beijing Tsinghua Chang Gung HospitalProspective AI-Assisted Screening of Biliary Tract Cancer Using Non-Contrast CT | 2026-11-30 |
| NCT04900818I-Mab Biopharma US LimitedStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | 2026-12 |
| NCT06792435Astellas Pharma Global Development, Inc.XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | 2026-12-30 |
Add all 39 to your calendar (.ics) → With an account.
Among the 176 studies in Biliary Tract Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label, single-arm trial will evaluate the anti-tumor activity of ZW25 (zanidatamab) monotherapy in subjects with human epidermal growth factor receptor 2 (HER2)-amplified, inoperable and advanced or metastatic biliary tract cancer (BTC), including intra-hepatic cholangiocarcinoma (ICC), extra-hepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ZW25 (Zanidatamab)
Administered intravenously
Also known as: JZP598, ZW25, ZIIHERA®
Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR)
Number of participants who achieved a confirmed best overall response (BOR) of either complete response (CR) or partial response (PR) during treatment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response (CR) is defined as a disappearance of all target and non-target lesions and partial response (PR) is defined as at least a 30% decrease in the sum of diameters of all target lesions.
Time frame: Up to 34 months
Duration of Response (DOR) by ICR
The time from the first confirmed objective response (CR or PR) to documented progressive disease (PD) per RECIST 1.1, or death from any cause
Time frame: Up to 45 months
DOR ≥ 16 Weeks by ICR
Proportion of subjects with a DOR ≥ 16 weeks per RECIST 1.1
Time frame: 24 weeks, up to 45 months
Disease Control Rate (DCR) by ICR
Number of subjects who achieved a best overall response of stable disease (SD), non-CR/non-PD, or confirmed CR or PR per RECIST 1.1
Time frame: Up to 45 months
Progression-free Survival (PFS) by ICR
The time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), or death from any cause
Time frame: Up to 45 months
ORR by Investigator Assessment
Number of subjects who achieved a confirmed BOR of either CR or PR during treatment per RECIST 1.1
Time frame: Up to 45 months
DOR by Investigator Assessment
The time from the first confirmed objective response (CR or PR) to documented progressive disease (PD) per RECIST 1.1, or death from any cause
Time frame: Up to 45 months
DOR ≥ 16 Weeks by Investigator Assessment
Proportion of subjects with a DOR ≥ 16 weeks per RECIST 1.1
Time frame: 24 weeks, up to 45 months
DCR by Investigator Assessment
Number of subjects who achieved a best overall response of stable disease (SD), non-CR/non-PD, or confirmed CR or PR per RECIST 1.1
Time frame: Up to 45 months
PFS by Investigator Assessment
The time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), or death from any cause
Time frame: Up to 45 months
Overall Survival
The time from the first dose of study treatment until the date of death from any cause
Time frame: Up to 45 months
Incidence of Adverse Events (AEs)
Number of subjects who experienced AEs or serious adverse events
Time frame: Up to 45 months
Incidence of Laboratory Abnormalities
Number of subjects who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0
Time frame: Up to 45 months
Maximum Serum Concentration of ZW25
Time frame: Pre-dose, end of infusion, 2, 4, 8, 24 and 96 hours post dose
Trough Concentration of ZW25
Minimum observed serum concentration (trough)
Time frame: Pre-dose, end of infusion, 2, 4, 8, 24 and 96 hours post dose
Incidence of Anti-drug Antibodies (ADAs)
Number of subjects who develop ADAs
Time frame: Up to 45 months
A total of 87 participants who met all eligibility criteria were enrolled and received treatment.
| Milestone | Cohort I | Cohort II |
|---|---|---|
| Started | 80 | 7 |
| Completed | 0 | 0 |
| Not completed | 80 | 7 |
| Withdrew: Death | 60 | 6 |
| Withdrew: Withdrawal by subject | 8 | 1 |
| Withdrew: Study terminated by sponsor | 5 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Transitioned to named patient supply (nps) program | 5 | 0 |
Number of participants who achieved a confirmed best overall response (BOR) of either complete response (CR) or partial response (PR) during treatment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response (CR) is defined as a disappearance of all target and non-target lesions and partial response (PR) is defined as at least a 30% decrease in the sum of diameters of all target lesions.
| Participants | Cohort I | Cohort II |
|---|---|---|
| Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR) | 33 | 0 |
The time from the first confirmed objective response (CR or PR) to documented progressive disease (PD) per RECIST 1.1, or death from any cause
| months | Cohort I | Cohort II |
|---|---|---|
| Duration of Response (DOR) by ICR | 14.92 (7.39 to 23.98) | — |
Proportion of subjects with a DOR ≥ 16 weeks per RECIST 1.1
| Participants | Cohort I | Cohort II |
|---|---|---|
| DOR ≥ 16 Weeks by ICR | 28 | — |
Number of subjects who achieved a best overall response of stable disease (SD), non-CR/non-PD, or confirmed CR or PR per RECIST 1.1
| Participants | Cohort I | Cohort II |
|---|---|---|
| Disease Control Rate (DCR) by ICR | 55 | 3 |
The time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), or death from any cause
| months | Cohort I | Cohort II |
|---|---|---|
| Progression-free Survival (PFS) by ICR | 5.49 (3.65 to 7.29) | 1.87 (1.22 to NA) |
Number of subjects who achieved a confirmed BOR of either CR or PR during treatment per RECIST 1.1
| Participants | Cohort I | Cohort II |
|---|---|---|
| ORR by Investigator Assessment | 34 | 0 |
The time from the first confirmed objective response (CR or PR) to documented progressive disease (PD) per RECIST 1.1, or death from any cause
| months | Cohort I | Cohort II |
|---|---|---|
| DOR by Investigator Assessment | 11.10 (7.46 to 14.06) | — |
Proportion of subjects with a DOR ≥ 16 weeks per RECIST 1.1
| Participants | Cohort I | Cohort II |
|---|---|---|
| DOR ≥ 16 Weeks by Investigator Assessment | 31 | — |
Number of subjects who achieved a best overall response of stable disease (SD), non-CR/non-PD, or confirmed CR or PR per RECIST 1.1
| Participants | Cohort I | Cohort II |
|---|---|---|
| DCR by Investigator Assessment | 54 | 1 |
The time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), or death from any cause
| months | Cohort I | Cohort II |
|---|---|---|
| PFS by Investigator Assessment | 5.37 (3.55 to 7.29) | 1.77 (0.79 to 1.94) |
The time from the first dose of study treatment until the date of death from any cause
| months | Cohort I | Cohort II |
|---|---|---|
| Overall Survival | 15.54 (10.38 to 18.66) | 5.52 (1.22 to NA) |
Number of subjects who experienced AEs or serious adverse events
| Participants | Cohort I | Cohort II |
|---|---|---|
| Any Treatment Emergent Adverse Event (TEAE) | 78 | 6 |
| Zanidatamab related TEAE | 61 | 2 |
| Any Treatment Emergent Serious Adverse Event | 43 | 3 |
| Zanidatamab related serious TEAE | 8 | 0 |
| Zanidatamab related TEAE resulting in treatment discontinuation | 2 | 0 |
Number of subjects who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0
| Participants | Cohort I | Cohort II |
|---|---|---|
| Incidence of Laboratory Abnormalities | 37 | 7 |
| micrograms per milliliter | Cohort I | Cohort II |
|---|---|---|
| Maximum Serum Concentration of ZW25 | 457.6 ± 15.44 | 443.6 ± 24.10 |
Minimum observed serum concentration (trough)
| micrograms per milliliter | Cohort I | Cohort II |
|---|---|---|
| Trough Concentration of ZW25 | 73.4 ± 42.10 | 46.5 ± 18.66 |
Number of subjects who develop ADAs
| Participants | Cohort I | Cohort II |
|---|---|---|
| Incidence of Anti-drug Antibodies (ADAs) | 1 | 0 |
Collected over Adverse events were collected from the start of dosing of any study drug up until 30 days after last study dose, up to approximately 45 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort I | 60/80 (75%) | 43/80 (53.8%) | 78/80 (97.5%) |
| Cohort II | 6/7 (85.7%) | 3/7 (42.9%) | 5/7 (71.4%) |
| Event | Cohort I | Cohort II |
|---|---|---|
| CholangitisHepatobiliary disorders | 3/80 | 2/7 |
| Hepatitis cholestaticHepatobiliary disorders | 0/80 | 1/7 |
| PneumoniaInfections and infestations | 4/80 | 1/7 |
| Biliary sepsisInfections and infestations | 0/80 | 1/7 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/80 | 1/7 |
| DyspepsiaGastrointestinal disorders | 0/80 | 1/7 |
| HaematemesisGastrointestinal disorders | 1/80 | 1/7 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/80 | 1/7 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/80 | 1/7 |
| Jaundice cholestaticHepatobiliary disorders | 5/80 | 0/7 |
| Event | Cohort I | Cohort II |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 39/80 | 0/7 |
| AnemiaBlood and lymphatic system disorders | 18/80 | 3/7 |
| Infusion related reactionInjury, poisoning and procedural complications | 27/80 | 1/7 |
| Blood alkaline phosphatase increasedInvestigations | 7/80 | 2/7 |
| Abdominal painGastrointestinal disorders | 16/80 | 0/7 |
| Alanine aminotransferase increasedInvestigations | 16/80 | 1/7 |
| Aspartate aminotransferase increasedInvestigations | 15/80 | 1/7 |
| NauseaGastrointestinal disorders | 14/80 | 0/7 |
| PyrexiaGeneral disorders | 14/80 | 0/7 |
| VomitingGastrointestinal disorders | 13/80 | 1/7 |
The baseline demographic characteristics were assessed in the Safety Analysis Set.
| Age, Continuous(years) | Cohort I | Cohort II | Total |
|---|---|---|---|
| Mean | 62.5 ± 9.56 | 65.4 ± 8.75 | 62.7 ± 9.48 |
| Sex: Female, Male(Participants) | Cohort I | Cohort II | Total |
|---|---|---|---|
| Female | 45 | 2 | 47 |
| Male | 35 | 5 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Cohort I | Cohort II | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 6 |
| Not Hispanic or Latino | 72 | 6 | 78 |
| Unknown or Not Reported | 3 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Cohort I | Cohort II | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 52 | 5 | 57 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 23 | 2 | 25 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.
Data sharing details ↗ · www.jazzpharma.com
Ran from Oct 2020 to primary completion in Jul 2023, 33 months.
Results were first posted in Aug 2024, 1 year after primary completion.
Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's 33 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanidatamab